Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Primary objective: To use overall survival to assess the efficacy of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan in the treatment of grade IV malignant glioma patients following surgical resection.
Secondary objective: To determine the progression-free survival following the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan.
Exploratory Objective: To explore the relationship between biomarkers and outcome (overall survival and progression-free survival) among patients with grade IV malignant glioma treated with radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan.
To describe the toxicity of radiation therapy,temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan.
| Condition | Intervention | Phase |
|---|---|---|
|
Glioblastoma Gliosarcoma Brain Tumor |
Drug: Avastin Drug: Temozolomide Radiation: Radiation Therapy (XRT) Drug: Irinotecan |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Avastin in Combination With Radiation and Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma Multiformes and Gliosarcomas |
- 16-month Overall Survival (OS) [ Time Frame: 16 months ] [ Designated as safety issue: No ]Percentage of participants surviving sixteen months from the start of study treatment. OS was defined as the time from the date of study treatment initiation to the date of death due to any cause.
- 12-month Progression-free Survival (PFS) [ Time Frame: 12 months ] [ Designated as safety issue: No ]Percentage of participants surviving twelve months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause.
- Number of Patients Experiencing a Central Nervous System (CNS) Hemorrhage or a Systemic Hemorrhage [ Time Frame: 55 months ] [ Designated as safety issue: Yes ]Number of times a CNS hemorrhage or systemic hemorrhage was experienced
- Number of Patients Experiencing a Grade ≥ 4 Hematologic or Grade ≥ 3 Non-hematologic Toxicity [ Time Frame: 55 months ] [ Designated as safety issue: Yes ]Number of times a grade ≥ 4 hematologic or grade ≥ 3 non-hematologic toxicity was experienced
| Enrollment: | 125 |
| Study Start Date: | July 2007 |
| Estimated Study Completion Date: | March 2013 |
| Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Avastin, radiation, temozolomide, and irinotecan |
Drug: Avastin
Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will have MRI and, if there is no evidence of disease progression, will receive treatment including 6 cycles of Avastin, which will begin a minimum of 14 days after last XRT. Avastin will be at a dose of 10 mg/kg. After 6 cycles, if MRI or PET show residual enhancement, the patient may continue.
Other Name: Bevacizumab
Drug: Temozolomide
Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will have MRI and, if there is no evidence of disease progression, will receive treatment including temozolomide at 200 mg/m2/day on the 1st 5 days of each 28-day cycle The treatment will continue for 6 cycles. After 6 cycles, if MRI or PET show residual enhancement, the patient may continue.
Other Name: Temodar
Radiation: Radiation Therapy (XRT)
Treatment with standard XRT (radiation) for 6.5 weeks.
Drug: Irinotecan
Following completion of XRT, patients will have MRI and, if there is no evidence of disease progression, will receive 6 cycles of treatment including irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). (EIAED will receive 340 mg/m2 every other week, non-EIAED will receive 125 mg/m2.) The treatment will continue for 6 cycles. After 6 cycles, if MRI or PET show residual enhancement, the patient may continue.
Other Names:
|
Detailed Description:
The standard of care for grade IV gliomas is radiation therapy with daily temozolomide, followed by 6 months of temozolomide. The majority of patients progress and die of their tumor. Many glioma patients are resistant to temozolomide because the tumors have high O(6)-methylguanine-DNA methyltransferase (MGMT), conferring resistance. Irinotecan is synergistic with temozolomide, and the combination may overcome high MGMT. Vascular endothelial growth factor (VEGF) is present on the cell surface and around malignant gliomas. It appears that the presence of vascular endothelial growth factor is a prognostic growth factor with more VEGF expression correlating with a poor prognosis. Monoclonal antibodies to VEGF have inhibited growth of malignant gliomas in a mouse xenograft. Avastin is a humanized monoclonal immunoglobulin G (IGG) 1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor. The combination of Avastin and irinotecan was safe and demonstrated high activity against recurrent malignant gliomas. The combination of Avastin, temozolomide, and irinotecan as the initial therapy may maximize the chance for long-term survival. There are other studies completed or ongoing for newly diagnosed glioblastoma (GBM) patients, including a Radiation Therapy Oncology Group (RTOG) study that added irinotecan to temozolomide following standard radiation therapy and temozolomide, and a University of California, Los Angeles (UCLA) study that added Avastin to standard radiation therapy and temozolomide followed by Avastin and temozolomide.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have histologically confirmed diagnosis of World Health Organization (WHO) grade IV primary malignant glioma (glioblastoma multiforme or gliosarcoma). Patients have to be within 4 weeks of the last major surgical procedure.
- Age > 18 years.
- An interval of at least 2 weeks and not > 6 weeks between prior major surgical procedure and study enrollment.
- No prior radiotherapy or chemotherapy for a brain tumor
- Karnofsky ≥ 60 percent.
- Hemoglobin ≥ 9.0 g/deciliter (dl), absolute neutrophil count (ANC) ≥ 1,500 cells/ microliter, platelets ≥ 125,000 cells/microliter.
- Serum creatinine ≤ 1.5 mg/dl, serum serum glutamic-oxaloacetic transaminase (SGOT) and bilirubin ≤ 1.5 times upper limit of normal (ULN).
- For patients on corticosteroids, they must be on a stable or decreasing dose for 1 week prior to entry, and the dose should not be escalated over entry dose level, if clinically possible.
- Signed informed consent approved by the Institutional Review Board
- No evidence of > grade 1 central nervous system (CNS) hemorrhage on the baseline MRI or CT scan.
- If sexually active, patients will take contraceptive measures for the duration of treatment as stated in the informed consent.
Exclusion Criteria:
- Pregnancy or breast feeding.
- Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids.
- Active infection requiring intravenous (IV) antibiotics.
- Prior treatment with radiotherapy or chemotherapy for a brain tumor, irrespective of the grade of the tumor.
- Evidence of > grade 1 CNS hemorrhage on baseline MRI on CT scan.
Avastin-Specific Concerns:
Subjects meeting any of the following criteria are ineligible for study entry:
- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study
- Blood pressure of 150/100 mmHg
- Unstable angina
- New York Heart Association (NYHA) Grade II or greater congestive heart failure
- History of myocardial infarction within 6 months
- History of stroke within 6 months
- Clinically significant peripheral vascular disease
- Evidence of bleeding diathesis
- Coagulopathy (prothrombin time (PT) or partial thromboplastin time (PTT) >1.5x normal or a history of > three grade 2 or greater hemorrhages)
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to first Avastin infusion during XRT/Temodar or anticipation of need for major surgical procedure during the course of the study
- Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to first Avastin infusion during XRT/Temodar
- Pregnant (positive pregnancy test) or lactating
- Urine protein >1.0 + at screening
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to first Avastin infusion during XRT/Temodar
- Serious, non-healing wound, ulcer, or bone fractures.
- Inability to comply with study and/or follow-up procedures.
Contacts and Locations| United States, North Carolina | |
| Duke University Health System | |
| Durham, North Carolina, United States, 27710 | |
| Principal Investigator: | Annick Desjardins, MD, FRCPC | Duke University Health System |
More Information
Additional Information:
No publications provided
| Responsible Party: | Duke University |
| ClinicalTrials.gov Identifier: | NCT00597402 History of Changes |
| Other Study ID Numbers: | Pro00000458 |
| Study First Received: | January 10, 2008 |
| Results First Received: | December 12, 2012 |
| Last Updated: | February 15, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Duke University:
|
Avastin Bevacizumab Temozolomide Temodar Irinotecan Camptosar GBM |
Glioblastoma Multiforme Gliosarcoma Brain tumor Glioma New GBM Newly diagnosed GBM or gliosarcoma malignant brain tumor |
Additional relevant MeSH terms:
|
Brain Neoplasms Glioblastoma Gliosarcoma Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Temozolomide Dacarbazine Irinotecan Bevacizumab Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Antineoplastic Agents, Phytogenic Radiation-Sensitizing Agents |
ClinicalTrials.gov processed this record on May 19, 2013